ORPHA:307
Juvenile myoclonic epilepsy
Also known as: JME · Juvenile myoclonus epilepsy
Publications
4,543
Trials
3
Interventional, condition-specific
Researchers
1,022
Distinct authors in sample
Gene link
EFHC1
Limited
Readiness
5/6
Stages with a signal
Clinical definition (Orphanet)
A rare syndrome characterized by adolescence/young adulthood onset of myoclonic with or without other generalized seizure types in an otherwise healthy individual. The electroencephalogram (EEG) shows 3-5.5 Hz generalized spike-waves and polyspike-waves. Photosensitivity is common.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0009696
- MeSH:D020190
- OMIM:254770
- OMIM:606904
- UMLS:C0270853
- NCIT:C84796
Additional Mondo synonyms (5)
EJM · epilepsy, myoclonic juvenile · juvenile myoclonus epilepsy · myoclonic epilepsy, juvenile · myoclonic epilepsy, juvenile, 1
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
5/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Limited — EFHC1
- LiteraturePresent
4,543 matched papers (2,287 in last 10 years) Source
- Phenotype characterisedPresent
20 HPO annotations (e.g. Myoclonic seizure; Bilateral tonic-clonic seizure; EEG with generalized polyspikes) Source
- Animal modelPresent
2 genotype models (Mus musculus) Source
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
3 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Possibly — only limited evidence so far for EFHC1.
GenCC classification: Limited.
Phenotypes (Monarch / HPO)
20
Associated phenotypes · MONDO:0009696
- Myoclonic seizure
- Bilateral tonic-clonic seizure
- EEG with generalized polyspikes
- Generalized non-motor (absence) seizure
- Intellectual disability
Showing 5 of 20 — open Monarch for the full list.
Animal models (Monarch / Alliance)
2
Model associations linked to this Mondo ID
- Efhc1tm1Kzy/Efhc1tm1Kzy [background:] B6.129P2-Efhc1tm1Kzy·MGI:3836724·Mus musculus
- Efhc1tm1Kzy/Efhc1+ [background:] B6.129P2-Efhc1tm1Kzy·MGI:3836725·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
2
Drugs / clinical candidates · MONDO_0009696
- LEVETIRACETAM·unknown
- STIRIPENTOL·approval
CTD chemicals (MyDisease.info)
3 associated chemicals · 30 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.
- Acetazolamide · therapeutic
- Levetiracetam · therapeutic
- Valproic Acid · therapeutic
Pathways: MAPK signaling pathway; Neuroactive ligand-receptor interaction; Cardiac muscle contraction; Adrenergic signaling in cardiomyocytes; Retrograde endocannabinoid signaling; GABAergic synapse; Taste transduction; Oxytocin signaling pathway
Literature
Is anyone studying this?
4,543
4,543 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
4,543 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
2,287 in the last 10 years · low confidence
Phrase hits: 4,238 · MeSH hits: 0
Who's working on it?
1,022
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Struck AF10 papers · 2026
Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Papers in Europe PMC - 02Hermann BP9 papers · 2026
Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Papers in Europe PMC - 03Prabhakaran V9 papers · 2026
Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Papers in Europe PMC - 04Adluru N8 papers · 2026
Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Papers in Europe PMC - 05Garcia-Ramos C8 papers · 2026
Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Papers in Europe PMC - 06Jones JE8 papers · 2026
Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Papers in Europe PMC - 07Adluru A6 papers · 2026
Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Papers in Europe PMC - 08Baykan B6 papers · 2026
Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Papers in Europe PMC - 09Li Y6 papers · 2025
Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.
Papers in Europe PMC - 10Nair V6 papers · 2026
Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
3
interventional trials for this specific condition
3 interventional trials matched this specific condition name; 1 currently recruiting in our sample. 1 trial are registered for myoclonic epilepsy, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 28 July 2026
3 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 86.7th percentile).
low confidence · 86.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
3 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07723963·NOT YET RECRUITING·A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy
Not reviewed·Conditions: Juvenile Myoclonic Epilepsy·Matched via name phrase
Broader category: myoclonic epilepsy
1
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT03400371·RECRUITING·Biology of Juvenile Myoclonic Epilepsy
Not reviewed·Conditions: Juvenile Myoclonic Epilepsy·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 62 · after dedupe 59 · already on CT.gov 1 · kept 0 · parent 0 · uncertain 58 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (58)
- isrctn·ISRCTN28271641·No longer recruiting·Indications for and consequences of antiepileptic drug withdrawal
skipped — LLM skipped (--skip-llm)
- ctis·2026-525162-21-00·Authorised·A Phase 2a, multi centric, open label clinical study to explore the safety and tolerability, the pharmacokinetics and pharmacodynamics profile and first signs of efficacy of PTI5803 administered as adjunctive therapy with a 3-dose escalation regimen in patients >= 14 years of age with drug-resistant seizures associated to focal cortical dysplasia, followed by an optional open-label extension study.
skipped — LLM skipped (--skip-llm)
- ctis·2025-521506-17-01·Authorised·iSTOP-CP: intranasal Stem Cells to treat Perinatal brain injury to combat Cerebral Palsy
skipped — LLM skipped (--skip-llm)
- ctis·2025-524019-35-00·Authorised, ongoing·Three-part PK and PD study of AXN-027
skipped — LLM skipped (--skip-llm)
- ctis·2026-525478-21-00·Authorised·A randomized, multiple ascending doses, clinical trial to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of CV-01 after double-blind, placebo-controlled multiple oral administrations for 2 weeks in healthy volunteers, and multiple oral administrations open-label for 2 weeks in a cohort of participants with drug resistant epilepsy
skipped — LLM skipped (--skip-llm)
- ctis·2025-524511-36-00·Authorised·Impact of epilepsy on the brainstem adenosine pathway and its relation with arousal and respiratory reactivity
BRAVE
skipped — LLM skipped (--skip-llm)
- ctis·2025-524134-26-00·Authorised, ongoing·Effect of NBI-921355 on corticospinal excitability in healthy participants
skipped — LLM skipped (--skip-llm)
- ctis·2025-522552-20-00·Authorised, recruiting·Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients with Lennox-Gastaut Syndrome
skipped — LLM skipped (--skip-llm)
- ctis·2025-524038-24-00·Authorised, recruiting·A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures
skipped — LLM skipped (--skip-llm)
- ctis·2025-524199-40-00·Authorised, ongoing·A PET-MRI study of serotoninergic brainstem pathway in patients with Dravet Syndrome - DRAPETONINE
skipped — LLM skipped (--skip-llm)
- ctis·2025-524310-28-00·Authorised, ongoing·A Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants
skipped — LLM skipped (--skip-llm)
- ctis·2025-520587-18-00·Authorised, ongoing·RENAISSANCE 2:
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures
skipped — LLM skipped (--skip-llm)
- ctis·2024-519133-29-00·Authorised·Efficacy of probenecid on cluster seizures during dosage reduction of Anti Seizure Medication (ASM) in presurgical focal epilepsy video-EEG monitoring
skipped — LLM skipped (--skip-llm)
- ctis·2025-521640-38-00·Authorised, ongoing·Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy.
skipped — LLM skipped (--skip-llm)
- ctis·2025-520541-72-00·Authorised, ongoing·NBI-1065845-MDD3027: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI 1065845 as an Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)
skipped — LLM skipped (--skip-llm)
- ctis·2024-519421-37-00·Authorised, ongoing·NBI-1065845-MDD3026: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)
skipped — LLM skipped (--skip-llm)
- ctis·2024-519420-25-00·Authorised, ongoing·NBI-1065845-MDD3025: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)
skipped — LLM skipped (--skip-llm)
- ctis·2024-519423-24-00·Authorised, recruiting·NBI-1065845-MDD3028: A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)
skipped — LLM skipped (--skip-llm)
- ctis·2024-519555-28-00·Authorised, recruiting·EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients with Dravet Syndrome
skipped — LLM skipped (--skip-llm)
- ctis·2024-519418-29-00·Authorised, ongoing·NBI-1065845-MDD3024: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)
skipped — LLM skipped (--skip-llm)
- ctis·2024-514937-39-00·Authorised, ongoing·A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with Dravet Syndrome
skipped — LLM skipped (--skip-llm)
- ctis·2024-517061-16-01·Cancelled·An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures
skipped — LLM skipped (--skip-llm)
- ctis·2024-514499-42-00·Authorised, recruiting·A Double-Blind, Randomized, Placebo and Active Controlled Study to Evaluate the Efficacy and Safety of Once Daily, Extended Release Levetiracetam as Add-on Therapy in Patients with Refractory Partial Onset Epilepsy.
skipped — LLM skipped (--skip-llm)
- ctis·2024-520427-86-00·Authorised, ongoing·Phase I, open-label clinical trial to evaluate the safety and clinical response of repeated-dose intra-arterial infusion of autologous mesenchymal cells in children and adolescents with refractory epilepsies.
skipped — LLM skipped (--skip-llm)
- ctis·2024-520171-27-00·Authorised, ongoing·Treatment with full-spectrum cannabis extract of refractory epilepsy associated with Tuberous Sclerosis Complex (TSC): SPECTRUM
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Juvenile myoclonic epilepsy — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Juvenile myoclonic epilepsy" OR "Juvenile myoclonus epilepsy" OR "epilepsy, myoclonic juvenile" OR "myoclonic epilepsy, juvenile" OR "myoclonic epilepsy, juvenile, 1") OR ("EFHC1" OR "EFHC1 syndrome" OR "EFHC1-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Juvenile myoclonic epilepsy" OR "Juvenile myoclonus epilepsy" OR "epilepsy, myoclonic juvenile" OR "myoclonic epilepsy, juvenile" OR "myoclonic epilepsy, juvenile, 1"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 3 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"myoclonic epilepsy"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: JME; EJM
Confidence reasoning
- Preferred label is multi-word and distinctive
- 2 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (4543) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T13:20:35.846Z
